Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drugs In Development, 2021

August 2021 | 81 pages | ID: GAB24D9B83E2EN
Global Markets Direct

Abstracts

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drugs In Development, 2021

SUMMARY

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 8 molecules. The latest report GrowthDifferentiation Factor 8 - Drugs In Development, 2021, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGF?) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 1 respectively.

Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Genetic Disorders, Hematological Disorders and Oncology which include indications Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Anemia, Becker Muscular Dystrophy, Beta Thalassaemia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Limb-Girdle Muscular Dystrophy, Muscle Wasting Disorders, Myelodysplastic Syndrome, Myelofibrosis, Neuromuscular Disorders, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) and Sarcopenia.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
• The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
• The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Overview
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Biogen Inc
Bioleaders Corp
Chugai Pharmaceutical Co Ltd
PeptiDream Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Scholar Rock Inc
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles
apitegromab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-22 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
domagrozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
luspatercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6237 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
Featured News & Press Releases
Jul 28, 2021: Acceleron announces second quarter 2021 REBLOZYL net sales
Jun 18, 2021: Scholar Rock to present Apitegromab TOPAZ phase 2 trial results highlighting pharmacokinetic (PK) and pharmacodynamic (PD) data at the 2021 European Academy of Neurology Congress
Jun 11, 2021: Scholar Rock presents TOPAZ phase 2 data showing the transformative potential of apitegromab in patients with type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
Jun 11, 2021: Bristol Myers Squibb and Acceleron present first results from phase 2 beyond study of Reblozyl (Luspatercept-aamt) In adults with non-transfusion dependent (NTD) beta thalassemia
Jun 07, 2021: Scholar Rock to present Apitegromab clinical data from the TOPAZ phase 2 trial in patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting
May 24, 2021: Scholar Rock receives fast track designation from the U.S. FDA for apitegromab for the treatment of patients with spinal muscular atrophy
May 12, 2021: Acceleron announces presentations on REBLOZYL (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress
May 11, 2021: Scholar Rock announces publication of phase 1 clinical trial data evaluating Apitegromab in healthy volunteers in the journal Advances in Therapy
Apr 26, 2021: Scholar Rock announces issuance of U.S. Patent broadly relevant to inhibitors of myostatin activation
Apr 06, 2021: Scholar Rock announces positive 12-month top-line results from the TOPAZ phase 2 clinical trial evaluating apitegromab in patients with type 2 and type 3 spinal muscular atrophy (SMA)
Mar 17, 2021: Scholar Rock announces issuance of U.S. patent protecting add-on or combination therapy with a myostatin inhibitor for the treatment of spinal muscular atrophy
Mar 15, 2021: Scholar Rock presents TOPAZ interim analysis data for Apitegromab in spinal muscular atrophy at the 2021 Muscular Dystrophy Association (MDA) virtual clinical & scientific conference
Feb 16, 2021: Health Canada approves REBLOZYL (luspatercept), new class of treatment for adult patients living with myelodysplastic syndromes
Feb 04, 2021: Acceleron announces fourth quarter and full year 2020 Reblozyl net sales
Nov 04, 2020: Rocket Pharmaceuticals to present data from its Fanconi Anemia, leukocyte adhesion deficiency-i and pyruvate kinase deficiency programs at the 62nd American Society of Hematology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Acceleron Pharma Inc, 2021
Pipeline by Biogen Inc, 2021
Pipeline by Bioleaders Corp, 2021
Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Pipeline by PeptiDream Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by Scholar Rock Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021